JWCA
RVMD icon

J.W. Cole Advisors’s Revolution Medicines RVMD Stock Holding History

J.W. Cole Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$510K Buy
2,722
+13
+0.5% +$1.9K 0.01% 1000
2026
Q1 		$263K Hold
2,709
– – 0.01% 662
2025
Q4 		$216K Buy
+2,709
New +$178K 0.01% 1268

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

J.W. Cole Advisors's RVMD Position: Q2 2026 in Review

J.W. Cole Advisors increased its Revolution Medicines (RVMD) stake by 0.48% in Q2 2026, buying an estimated $1.9K and bringing the position to 2,722 shares worth $510K. The position accounts for 0.01% of the portfolio, ranked #1000.

J.W. Cole Advisors first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • J.W. Cole Advisors held 2,722 shares of Revolution Medicines worth $510K as of Q2 2026.
  • J.W. Cole Advisors bought 13 Revolution Medicines shares in Q2 2026, an estimated $1.9K.
  • Revolution Medicines made up 0.01% of J.W. Cole Advisors's portfolio in Q2 2026, its #1000 holding.
  • J.W. Cole Advisors first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on J.W. Cole Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.